Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report issued on Friday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 6.0 %

NYSE BTX opened at $0.42 on Friday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm’s fifty day simple moving average is $0.44 and its 200-day simple moving average is $1.11. The company has a market capitalization of $24.84 million, a PE ratio of -0.19 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.